Having provided proofs through molecular silencing studies of the involvement of PACE4 in prostate cancer progression, we then turned our attention to small-molecule pharmacological inhibitors that could be applied exogenous to these cell lines and eventually be tested in vivo. This evidence concerns the gene PCSK6 and Familial prostate cancer.